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Abstract 
Although many clinicopathological studies of
malignant melanoma of the conjunctiva have
been reported, there have been no studies of
the expression and gene mutations of KIT and
PDGFRA in melanoma of the conjunctiva. A 69-
year-old Japanese woman consulted our hospi-
tal because of black mass (0.7 x 0.7 x 0.6 cm) in
the conjunctiva. A biopsy was taken. The biopsy
showed  malignant  epithelioid  cells  with
melanin  deposition.  Immunohistochemically,
the  tumor  was  positive  for  S100  protein,
HMB45,  p53,  Ki-67  (labeling=30%),  KIT  and
PDGFRA. The tumor was negative for pancytok-
eratins (AE1/3 and CAM5.2). A genetic analysis
using  PCR-direct  sequencing  revealed  no
mutations of KITgene (exons 9, 11, 13, and 17)
and  PDGFRA gene  (exons  12  and  18).  The
pathological  diagnosis  was  conjunctival
melanoma. Despite chemotherapy, the patient
developed  multiple  metastases  of  melanoma,
and died of melanoma 7 years after the biopsy.
In conclusion, the author reported a case of
melanoma of conjunctive expressing KIT and
PDGFRA  proteins  without  gene  mutations  of
KIT and PDGFRA. 
Introduction
Malignant melanoma is a highly malignant
tumor,  and  NRAS and  BRAF mutations  are
mainly  involved  in  the  pathogenesis  of
melanoma.1,2 KIT gene,  mapped  to  4q12,
encodes  an  oncogenic  transmembranous
receptor tyrosine kinase, KIT, whose ligand is
stem cell factor.3 The platelet derived growth
factor receptor-α (PDGFRA) gene, also mapped
to 4q12, also encodes an oncogenic transmem-
branous  receptor  tyrosine  kinase,  PDGFRA.3
The KIT gene plays an important role in the
melanocyte migration, development, differen-
tiation  and  tumorigenesis.4 Previous  studies
have shown that activating mutations of the
KIT gene may lead to tumorigenesis of cuta-
neous  melanoma.1 Since  KIT and  PDGFRA
genes  are  mapped  to  4q12,  it  is  anticipated
that PDGFRA gene mutations are involved in
the tumorigenesis of melanoma, as in the case
of gastrointestinal stromal tumors.3 However,
PDGFRA gene  mutations  in  melanoma  have
rarely been examined.5-8 In addition, PDGFRA
protein expression has rarely been analyzed in
melanoma.  These  studies  have  been  per-
formed in Caucasians, and only two reports by
Ashida  et  al.6 and  ours7 is  available  in
Mongoloids,  including  Japanese  in  which
malignant  melanoma  is  much  more  uncom-
mon than in Caucasians.9 Ashida et al.6 report-
ed  that  KIT  protein  expression  was  48%  in
Japanese cutaneous melanoma and that KIT
mutations  were  16%  in  Japanese  cutaneous
melanoma. Our previous study7has shown that
KIT and  PDGFRA expression  in  cutaneous
melanoma  was  present  in  92%  and  100%,
respectively,  and  that  mutations  of  KIT  and
PDGFRA  were  recognized  in  8%  and  0%,
respectively, in cutaneous melanoma.
Although  many  clinicopathological  studies
on melanoma of conjunctiva have been per-
formed,10,11 there have been no studies of KIT
and PDGFRA in melanoma of the conjunctiva.
The  author  investigated  the  protein  expres-
sion  and  gene  mutation  status  of  KIT and
PDGFRA in a case of conjunctival melanoma of
a Japanese woman. 
Case Report
A  69-year-old  Japanese  woman  consulted
our hospital because of black mass in the con-
junctiva.  Physical  examination  revealed  a
black tumor measuring 0.7¥0.7¥0.6 cm of the
right conjunctiva. A biopsy was taken, and the
biopsy showed malignant epithelioid cells with
brown  pigment  deposition  (Figure  1).  The
brown  pigment  was  positive  with  Fontana-
Masson stain, and therefore was thought to be
melanin.  An  immunohistochemical  analysis
was performed, using Dako’s Envision method,
as  previously  described.12-14 Immunohisto  -
chemically, the tumor cells were positive for
S100 protein (Figure 2), HMB45 (Figure 3),
p53, Ki-67 (labeling=30%), KIT (Figure 4) and
PDGFRA (Figure 5). The tumor was negative
for pancytokeratins (AE1/3 and CAM5.2).
Genetic analyses of the KIT gene (exons 9,
11, 13, and 17) and PDGFRA (exons 12 and 18)
gene  were  performed  by  the  PCR  direct
sequencing method, as previously reported.15-19
The exons of both genes were selected because
they are frequent mutation sites.3 The primers
are shown in Table 1. In brief, genomic DNA
was extracted from paraffin blocks with pro-
teinase  K  digestion  and  phenol/chloroform
extraction, and subjected to PCR for 40 cycles
(94°C for one min, 52°C for one min, 72°C for
one min), using a thermal cycler (GeneAmp
PCR  system  9700,  Applied  Biosystems,  ABI,
CA).  The  annealing  temperature  was  53°C.
PCR products were extracted, and subjected to
a  computed  automatic  DNA  sequencer  (ABI
PRISM  3100  Genetic  Analyzer,  Applied
Biosystems,  ABI,  CA).  These  techniques
revealed that there were no mutations of the
KIT gene  (exons  9,  11,  13,  and  17)  and
PDGFRA gene (exons 12 and 18) in this tumor.
The pathological diagnosis was conjunctival
melanoma. Despite chemotherapy, the patient
developed multiple metastases of melanoma,
and died of melanoma 7 years after the biopsy. 
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Table 1. Primer sequence.
Forward Reverse
KIT exon 9 5’-TCC TAG AGT AAG CCA GGG CTT-3’ 5’-TGG TAG ACA GAG CCT AAA CAT CC-3’
KIT exon11 5’-GAT CTA TTT TTC CCT TTC TC-3’ 5’AGC CCC TGT TTC ATA CTG AC-3’
KIT exon 13 5’-GCT TGA CAT CAG TTT GCC AG -3’ 5’-AAA GGC AGC TTG GAC ACG GCT TTA-3’
KIT exon 17 5’-CTC CTC CAA CCT AAT AGT GT-3’ 5’-GTC AAG CAG AGA ATG GGT AC-3’
PDGFRA exon12 5’-TTG GAT ATT CAC CAG TTA CCT GTC-3’ 5’-CAA GGG AAA AGC TCT TGG-3’
PDGFRA exon 18 5’-ACC ATG GAT CAG CCA GTC TT-3’ 5’-TGA AGG AGG ATG AGC CTG ACC-3’[page 22] [Rare Tumors 2012; 4:e8]
Discussion
The  present  case  is  the  second  report  of
PDGFRA protein status in melanoma and is the
first in conjunctival melanoma. Our previous
study7 showed  100%  expression  of  PDGFRA
protein in cutaneous melanoma. The present
study is the forth report of PDGFRA mutations
in melanoma; the first was reported by Curtin
et al.,5 who found no PDGFR mutations in 26
cutaneous melanomas. The second was report-
ed  by  Sihto  et  al.,20 who  demonstrated  no
PDGFRA gene  mutations  in  14  cutaneous
melanomas. The third was reported by us; no
mutations of PDGFRA gene were found in 12
cutaneous melanomas. The current case is the
first report of PDGFRA gene status in the con-
junctival melanoma. 
The present case showed no mutations of
the KIT gene. Studies of KIT mutations are
scant in number in cutaneous melanoma, and
are none in conjunctival melanoma. Willmore-
Payne et al.21 showed only 2% of melanomas
had KIT mutations. Sihto et al.20 showed no
KIT mutations in 14 cutaneous melanomas. In
contrast, Curtin et al.1 showed that KIT muta-
tions  were  present  in  39%  of  mucosal
melanomas, in 36% of acral melanomas, 28%
in melanomas of sun-damaged skin, and in 0%
of  melanomas  of  non-sun-damaged  skin.
Beadling  et  al.22 recently  reported  that  KIT
mutations  were  present  in  23%  of  acral
melanomas,  15.6%  of  mucosal  melanomas,
1.7%  of  cutaneous  melanomas,  and  0%  of
choroidal melanomas. Handolias et al.23 report-
ed that KIT mutations were present in 2% of
melanomas and that KIT mutations were fre-
quent  in  acral  and  sun-damaged  skin
melanomas and mucosal melanomas while it
was  very  rare  in  non-sun-damaged  skin
melanoma. In the present case, no mutations
were seen in the KIT gene. Since KIT muta-
tional  studies  are  scant  in  conjunctival
melanoma,  more  studies  remain  to  be  per-
formed.
The present case showed positive KIT pro-
tein expression in conjuctival melanoma. The
percentage  of  KIT  expression  in  cutaneous
melanomas varies among researchers. There
have been no reports of KIT expression in con-
junctival melanoma, to the best of our knowl-
edge. The percentage in the literature ranges
from 21 %24 to 84%.25 Sihto et al.20 reported that
KIT expression in most human solid tumors,
including melanomas, were due to KIT gene
amplification. More studies of the relationship
between KIT gene mutations and KIT protein
expression in conjunctival melanoma remain
to be performed. 
In conclusion, the author reported a case of
melanoma of conjunctiva expressing KIT and
PDGFRA proteins without gene mutations of
KIT and PDGFRA. Because this is only a case
report,  examinations  of  larger  number  of
patients are needed.
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